koto_feja/E+ via Getty Images
Nektar (NKTR) hasn’t been doing too well lately, despite a data-rich year ahead; and the fall started after poor revenue figures from February, as well as from May. However, it doesn’t have approved products any longer; in…
Nektar In Renal Cell Carcinoma: An Overview
Share this article
More News

Analysts see 15% upside on AI growth
October 12, 2026


What Investors Need To Know
October 12, 2026




Halifax
October 12, 2026